Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12044316 | 0.83 | GRIN2D (0.57) | KMT2AMEN1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL28464450 | 0.83 | MEN1 (1.00) | KMT2AMEN1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL30733225 | 0.83 | MEN1 (1.00) | KMT2AMEN1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1507696 | 0.77 | MAPT (0.78) | KMT2AMEN1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL19748575 | 0.76 | KDR (0.81) | KMT2AMEN1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL24239276 | 0.75 | KMT2A (0.60) | KMT2AMEN1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL19422863 | 0.75 | MAPT (1.00) | KMT2AMEN1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL29832141 | 0.75 | MAPT (1.00) | KMT2AMEN1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL12172758 | 0.75 | MAPT (0.75) | KMT2AMEN1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL27782316 | 0.75 | MAPT (0.71) | KMT2AMEN1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200299251-A1 | FURAN SKELETON-CONTAINING IMINOGUANIDINE DERIVATIVE AS WELL AS PREPARATION AND APPLICATION THEREOF | SUN YAT-SEN UNIVERSITY | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299251-A1 | FURAN SKELETON-CONTAINING IMINOGUANIDINE DERIVATIVE AS WELL AS PREPARATION AND APPLICATION THEREOF | S100A9, IMPDH2, PNP | KMT2A 4601/4885MEN1 2500/4885RAB9A 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.